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Abstract
Microscopic colitis (MC) is an inflammatory bowel disease presenting with chronic, non-bloody
watery diarrhoea and few or no endoscopic abnormalities. The histological examination reveals
mainly two subtypes of MC, lymphocytic or collagenous colitis. Despite the fact that the
incidence in MC has been rising over the last decades, research has been sparse and our
knowledge about MC remains limited. Specialists in the field have initiated the European
Microscopic Colitis Group (EMCG) with the primary goal to create awareness on MC. The EMCG is
furthermore a forum with the intention to promote clinical and basic research. In this article
statements and comments are given that all members of the EMCG have considered being of
importance for a better understanding of MC. The paper focuses on the newest updates in
epidemiology, symptoms and diagnostic criteria, pathophysiology and highlights some unsolvedt of Gastroenterology, Linköping University Hospital, SE-58185 Linköping, Sweden. Tel.: +46 101030000;
.se (A. Münch).
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933Statements on microscopic colitisproblems. Moreover, a new treatment algorithm is proposed on the basis of new evidence from
well-designed, randomized control trials.
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cause of chronic, non-bloody diarrhoea. Epidemiological
studies have shown a rising incidence in the last decade. The
diagnosis rests on specific histological findings in colonic
biopsies from patients with chronic diarrhoea demonstrating
either lymphocytic colitis (LC) or collagenous colitis (CC).Proper diagnosis and regular follow-ups are important to
differentiate these patients from those with irritable bowel
syndrome (IBS), to provide relevant treatment, and to improve
quality of life.
In comparison with the other inflammatory bowel diseases
(IBD), our knowledge about MC remains limited. More research
is needed to investigate the aetiology and pathophysiology of
MC, but above all more clinical studies are needed to improve
the handling of MC patients.
934 A. Münch et al.To address these apparent shortcomings, physicians dedi-
cated to the understanding of MC met in September 2010 in
Stockholm, Sweden to found the European Microscopic Colitis
Group (EMCG). The primary objective of the EMCG is to create
awareness on MC among patients, general practitioners,
gastroenterologists, surgeons, and pathologists on all aspects
of MC, and to eliminate misconceptions. Another aim is to
promote collaboration among the EMCG members in clinical
trials and basic science. In the long run this should result in the
recommendation of evidence-based guidelines which can
improve the care of MC patients.
Each topic in this article was initially written by 1–3 authors
and discussed and revised at two meetings by all members of
the EMCG. All members agreed on statements which are
considered to be of importance for the understanding of MC.
The statements are highlighted in the text and further
explained and specified in comments. The paper focuses on
the newest updates in epidemiology, symptoms and diagnostic
criteria, pathophysiology, and treatment guidelines, and gives
an overview of unsolved problems and future aspects. Since
only limited knowledge is available regarding some of these
topics, this document should be read as the best attempt to
inform about clinical practice and knowledge in areas where
rigorous evidence may not yet be available. However, we
propose a new treatment algorithm on the basis of additional
recent evidence from multiple well-designed, randomized
controlled studies.2. Epidemiology
2.1. MC is a common cause of chronic diarrhoea,
especially in the elderly
Epidemiologic studies show that MC is almost as common as
classic IBD (i.e. Crohn's disease and ulcerative colitis).1–3
Epidemiologic data have now been reported from fiveTable 1 Annual incidence per 100,000 inhabitants in
population-based epidemiological studies of collagenous
and lymphocytic colitis.
Region and study period Collagenous
colitis
Lymphocytic
colitis
Örebro, Sweden 1984–198821 0.8
Örebro, Sweden 1989–199321 2.7
Örebro, Sweden 1993–19951 3.7 3.1
Örebro, Sweden 1996–19981 6.1 5.7
Örebro, Sweden 1999–20032 4.7 5.1
Örebro, Sweden 2004–20082 5.8 4.5
Terassa, Spain 1993–199722 1.1 3.1
Terassa, Spain 2004–200819 2.6 2.2
Iceland 1995–199916 5.2 4.0
Olmsted County, Minnesota,
USA 1985–19973
1.6 2.7
Olmsted County, Minnesota,
USA 1998–20013
7.1 12.6
Calgary, Canada 2002–200423 4.6 5.4
Calgary, Canada 2004–200818 7.2 14.0
Zeeland, Denmark 2002–201017 10.8 6.7different regions in Europe and North America. In recent
years there have also been reports of cases and cohorts with
MC from Africa, Asia, Latin America, and Australia, proving it
to be a worldwide condition.4–9 Microscopic colitis may be
diagnosed in 10% of patients investigated for chronic non-
bloody diarrhoea, and in 20% or more of such patients older
than 70 years.10,11 This observation is very important in the
management of diarrhoea patients, but the disease must
also be considered in younger patients, as 25% of MC patients
are diagnosed before the age of 45 years.12 MC has been
reported in a few children below the age of 12, but is
apparently a rare phenomenon in childhood.13–15
After a period of rising incidence figures, the data have
been more divergent in recent studies. Incidence rates of 2.6/
100,000 to 10.8/100,000 inhabitants have been reported for
CC, and incidence rates of 2.2 to 14 per 100,000 inhabitants
for LC.1–3,16 To date, the highest incidence for MC was
reported from USA,3 Denmark17 and Canada18 while in more
southern regions (e.g. Spain) the incidence seems to be lower
(Table 1).19 These reports indicate that MC ismore frequent in
the northern countries and follow a north–south gradient.
However, a recent report from USA fails to support the notion
of a north–south gradient regarding the incidence of MC in the
USA.20
Patients with MC are typically elderly women, and the
average age at diagnosis is approximately 65 years. The
female predominance is very obvious in MC, but is less
pronounced for LC than for CC. Recent prevalence estimates
for MC are 103 cases per 100,000 persons (42 for CC and 69
for LC).32.2. Smoking is a risk factor for MC
Little is known about environmental risk factors in these
diseases. However, smoking has been studied in three cohort
studies. The first one revealed that smoking was significantly
more frequent in CC than in controls and smokers developed
their disease 10 years earlier than non-smokers,24 results which
were corroborated in a recent Spanish study.25 In another
study, more MC patients than controls were smokers; previous
or current smoking yielded an OR of 2.4 (1.5–3.8) for CC
(pb0.001) and 1.6 (1.0–2.5) for LC (pb0.05).26,273. Clinical features and health-related quality
of life
3.1. Chronic non-bloody diarrhoea is the main
clinical feature of MC
The main symptom of MC is chronic, non-bloody diarrhoea
that may be accompanied by nocturnal diarrhoea, faecal
incontinence and mild weight loss.12,17,28 Abdominal pain is
significantly more common in CC compared with a background
population.26 Serious dehydration and mucus or blood in the
stool are rare. LC is clinically indistinguishable from CC. In two
reports, however, it was found that symptoms in LC were
milder and more likely to disappear than those in CC.11,29,30
935Statements on microscopic colitis3.2. The natural course of MC is largely unknown,
but appears to differ between CC and LC
The onset of the disease is often insidious, but in about 40%
of patients it is sudden.12 In most cases, the clinical course is
chronic relapsing and benign.10,31–34 In earlier small follow-
up studies of CC, a majority of patients, mostly without
treatment, had lasting remission after 3–4 years,35,36 which
is in accordance with a more recent study from Iceland.34
For LC a benign course was reported, with resolution of
diarrhoea and normalization of histology in over 80% of
patients. According to Olesen et al., in 63% of patients the
clinical course is a single attack.11
On the other hand, prospective studies show high relapse
rates up to 60% after cessation of budesonide.37,38 Furthermore,
in a number of patients the course can be complicated due
to lack of response to medication. Surgery with a diverting
ileostomy or colectomy is an option in patients with refractory
and severe symptoms.12,33,39,40
3.3. MC is often associatedwith autoimmune diseases
Autoimmune disorders such as rheumatic disease, coeliac
disease, thyroid disease, and diabetes were more often
reported in patients than in controls, with an odds ratio of
11.0 (5.1–23.8) for CC patients (pb0.001).26
Autoimmune diseases have also been reported in LC
patients. The odds ratio for LC patients of having one or
more associated autoimmune diseases is 16.6 (6.4–43.1,
pb0.001).26
3.4. MC-related complications are rare
Serious complications are uncommon, though there have
been a few reports of patients with colonic perforation.41–43
Perforation seems to be related to ‘mucosal tears’ that can
be seen at colonoscopy.44–48 Some authors have concluded
that the risk for colorectal cancer is the same as in the
general population,49–51 while conversely a recent case–
control study concluded that MC patients show a decreased
risk.52
3.5. Health-related quality of life is significantly
reduced in MC
The symptoms of CC may impair patients' health-related
quality of life (HRQL).53
There is still no valid biomarker to define disease activity
in CC. Clinical trials have used various different definitions
for relapse or clinical response, making it difficult toTable 2 Definition of clinical disease activity in
collagenous colitis.
Stools per
day a
Watery stools
per day a
Clinical remission b3 AND b1
Clinical activity ≥3 OR ≥1
a Mean during a one-week symptom registration.compare results.37,38,54–58 However, a definition of clinical
remission has now been proposed, based on the finding of a
natural “break-point” between high and low impact of
bowel symptoms on HRQL in patients with CC.59 In a survey
of 116 patients with CC, stool frequency and consistency
were found to give a clear cut-off to define remission. CC
patients with a mean of b3 stools per day and a mean of b1
watery stool/day during a one-week symptom registration
were defined as being in remission, since they had no or only
mild impact on their HRQL. In contrast, CC patients with
either ≥3 stools/day or ≥1 watery stool/day had a
significant impact on their HRQL and were thus defined as
having active disease (Table 2). Further prospective valida-
tion of this definition of disease activity in CC is needed,
preferably in a prospective study where change in stool
frequency or consistency over the defined “break-point”
should result in a similar significant change in HRQL.
4. Diagnostic criteria and spectrum of micro-
scopic colitis
4.1. Colonoscopy withmultiple colonic biopsies is the
main diagnostic procedure to establish the diagnosis
and to rule out other causes of diarrhoea4.1.1. Bile acid diarrhoea, coeliac disease, and lactose
malabsorption should be considered
The diagnosis of MC rests on characteristic pathological
findings in biopsies from normal or oedematous colonic
mucosa. Although the topographic distribution of MC remains
controversial, rectal biopsies do not suffice.60,61 Some studies
demonstrate that biopsies from the right and transverse colon
are necessary for the diagnosis of CC,61,62 while others
demonstrate that biopsies from the descending and sigmoid
colon suffice for diagnosing MC.17,63–65 However, colonoscopy
should be preferred because it is essential to rule out
malignant colonic disease. Diarrhoea caused by other diseases
should be excluded; these diseases include bile acid diarrhoea,
coeliac disease, and lactose malabsorption. Other imaging
procedures are not recommended.Figure 1 Biopsy from colon showing typical findings of lympho-
cytic colitis: inflammation of lamina propria, intraepithelial infiltra-
tion with lymphocytes and epithelial lesions.
Figure 3 Histological features of collagenous colitis: an increased
subepithelial collagenous layer (van Gieson staining), inflammation
of lamina propria, intraepithelial infiltration with lymphocytes and
epithelial lesions.
936 A. Münch et al.4.1.2. Diagnosis of MC is based on clinical symptoms and
histology
Histologically, MC is comprised of two well-defined entities:
lymphocytic colitis (LC) and collagenous colitis (CC). As LC and
CC share clinical similarities and histopathological fea-
tures,61,64,66,67 there has been some discussion of whether
the two are in fact different stages of disease development.68
However, conversion of LC to CC or vice versa is infrequent,
and at present LC and CC are considered two separate but
related entities.69
Chronic inflammation in the lamina propria is hard to
define. In MC, the lamina propria shows increased numbers
of plasma cells and lymphocytes with loss of the normal
gradient (plasma cells around the crypt bases).70 Eosinophil
and neutrophil granulocytes may also be present in the
lamina propria and sometimes within the epithelium.71
Focally, active cryptitis with intraepithelial neutrophil
granulocytes may be encountered.
Histological findings of MC are fairly inconsistent with
repeat endoscopy.17,61,72 It is possible that the inflammation
in lamina propria is more important for the symptoms than
the changes characterizing the MC subtypes.66,72–74 This
notion is supported by the lack of correlation between
symptoms and either the thickness of the subepithelial
collagenous layer or the number of intraepithelial lympho-
cytes (IELs).72Figure 2 Lymphocytic colitis: note the increased numbers of
intraepithelial lymphocytes and inflammatory infiltrate in the
lamina propria after staining for CD3.4.1.3. The key histological feature of LC is an increased
proportion of surface intraepithelial lymphocytes (N20 IELs
per 100 epithelial cells) (Fig. 1)
The general opinion in the literature is that N20 IELs per
100 epithelial cells are required to warrant a diagnosis
of LC.71,75–77 Epithelium overlying lymphoid follicles should
not be evaluated. The number of IELs is greatest in the
ascending and transverse colon and lowest in the rectosigmoid
colon. IELs are T-lymphocytes, mostly cytotoxic CD8-positive
T-lymphocytes. The epithelium itself can show regressive
changes, with focal or diffuse flattening of the columnar cells,
loss of mucin, decreased goblet cells, and signs of degener-
ation such as cytoplasmic vacuoles and pyknotic nuclei. The
nuclei in the colonic crypts may be enlarged, with slightly
increased mitoses. The crypts are normal in size, shape, and
architecture. Very rarely, some epithelial multinucleated
giant cells and collections of macrophages may be seen, as
well as Paneth cell metaplasia distal to the transverse colon.78
In borderline cases or in cases of uncertainty, it is highly
recommended to perform CD3 staining (Fig. 2) in order to
determine the precise number of IELs and to confirm the
diagnosis.784.1.4. The key histological feature of CC is a broad
subepithelial fibrous bandN10μm in thickness, immediately
underneath the surface epithelium (Fig. 3)
Mucosal inflammation with slightly to moderately increased
numbers of lymphocytes and plasma cells, admixed with mast
cells and variable numbers of eosinophils and neutrophils is
another hallmark of CC (Fig. 3).71,76,77 The collagen band can
contain entrapped capillaries, red blood cells, and inflamma-
tory cells.75 There is almost no extension of the thickened
collagen table around the crypts. It is important to use only
well-oriented biopsies for the analysis of subepithelial colla-
gen, since tangential sectioning of tissue may mimic a
thickened collagen table. The epithelium itself may show
vacuolization and desquamation as well as increased IELs
(though not as many as seen in LC).79 Damaged epithelial cells
appear flattened, mucin-depleted, and irregularly oriented.
Focally, small strips of surface epithelium may lift off from
their basement membrane.80
Table 3 Factors and mediators involved in the
pathophysiological mechanism of MC.
Factors Mediators References
Cellular -Predominance of CD 8+
T lymphocytes carrying the α/β
form.
101
-Increased infiltration of
functional active eosinophils.
102
-Increased CD25+FOXP3+
lymphocytes.
74
Altered
collagenous
deposition
-Stains for collagen types III and
VI, and particularly for
tenascin.
81,103
-Imbalance of fibrogenesis and
fibrolysis due to restricted matrix
metalloproteinase (MMP-1) RNA
and increased tissue inhibitor of
metalloproteinases (TIMP)
expression.
103,104
-Increased transforming growth
factor-β1 (TGF-β1), which may
be of pathophysiological impor-
tance in connective tissue
remodelling.
105
-Increased expression of
connective tissue growth factor
(CTFG) as a mediator of cellular
collagen production.
106
-Vascular endothelial growth
factor (VEGF) might play a role
in the accumulation of
immature subepithelial matrix
and intestinal inflammation.
107,108
-Subepithelial myofibroblasts
might be involved in the
formation of the subepithelial
collagen band.
81,109
Cytokines -CC demonstrates a Th1
mucosal cytokine profile with
interferon gamma (IFN γ) as the
predominantly upregulated
cytokine. Mucosal mRNA levels
of interleukin (IL) 15 and
tumour necrosis factor alpha
(TNF-α) are increased.
110
-Increased expression of iNOS
correlates with luminal nitric
oxide (NO) concentrations and
clinical activity.
111
-NFЌB is activated and recruited
to the iNOS promoter in vivo via
an IKKβ mediated pathway.
112
Faecal
markers
-Eosinophil protein X, myelo-
peroxidase, and tryptase can be
increased in CC.
113
-Results for calprotectin are
contradictory and it cannot be
recommended as a diagnostic
tool.
114
937Statements on microscopic colitisIn cases of uncertainty, tenascin staining is recommended
for better visualization and measurement of the collagen
band thickness.81
4.1.5. Patients with chronic diarrhoea not fulfilling the
histological CC/LC criteria may have incomplete MC (MCi)
Fraser has suggested the term “MC not otherwise specified”
(MCnos) for a subgroup of patients with diarrhoea, an increase
in cellular infiltrate in the colonic lamina propria, and either
an abnormal collagenous layer or IELs short of fulfilling the
criteria for CC and LC.82 Similarly, the term “paucicellular
lymphocytic colitis” has been proposed for patients with
typical clinical symptoms of MC and increased numbers of
colonic IELs not fulfilling the diagnostic cut-off for LC.74
Others have also reported such patients with clinical charac-
teristics indistinguishable from LC and CC.72,74,83 Uncontrolled
data suggest that these patients respond to budesonide aswell
as patients with MC.17 Prospective studies are needed to
describe this possible third subgroup of MC and the effect of
medical treatment.
5. Aetiology and pathophysiology
5.1. Familial occurrence of MC has been reported,
but the role of genetic factors remains unclear
Familial microscopic colitis has been reported in small
numbers.84,85 Human leukocyte antigen (HLA) studies have
demonstrated an association between MC and HLA-DQ2 or
DQ1/3, as well as a higher frequency of HLA-DR3DQ2 haplotype
and TNF2 allele carriage in MC compared with controls.86–88
Furthermore, allelic variation of the matrix metalloproteinase-
9 gene does appear to be associated with CC.89 In contrast to
Crohn's disease, functional polymorphism in the NOD2/CARD15
gene has not been detected.90
5.2. Epithelial barrier function is compromised in MC
In vitro experiments on colonic biopsies revealed a significant
mucosal barrier dysfunction in CC patients in clinical remission,
which was aggravated in active disease presenting with
increased transmucosal uptake of non-pathogenic bacteria.
The mucosal barrier dysfunction even persisted despite
clinically effective short-term treatment with budesonide.91
It is though uncertain if the underlying mucosal dysfunction is a
primary or secondary phenomenon. On the other hand, the
small bowel mucosa integrity seems intact, as assessed with
urinary excretion after ingestion of 14C-labelled mannitol and
99mTc-labelled diethylenetriamine-pentaacetic acid.92
5.3. Mechanism of diarrhoea includes secretory and
osmotic components
Bürgel et al. used an Ussing chamber technique to reveal the
diarrhoeal mechanism in CC as being a reduced Na+ and Cl−
absorption accompanied by a secretory component of active
chloride secretion.93 Analysis of faecal electrolytes also
suggested a secretory mechanism.94 The severity of diarrhoea
seems to be best reflected by the intensity of inflammation in
the lamina propria and is not correlated to the thickness of
938 A. Münch et al.the collagenous band,95 indicating that the diarrhoea is of
inflammatory origin. The clinical observation that fasting can
reduce diarrhoea indicates an osmotic component,96 making it
likely that the watery stools in MC are driven by a combination
of osmotic and secretory components.
5.4. Bile acid diarrhoea is frequently seen in MC
By using selenium-labelled homocholic acid-taurine (SeHCAT),
concurrent bile acid malabsorption (BAM) was shown to
frequently exist in patients with CC (up to 44% of patients)97,98
and LC.17,97 It remains to be elucidated whether the association
between BAM and MC is causal. No association was found
between cholecystectomy and MC.99 Uncontrolled data
indicate that bile acid binding treatment is effective in
MC, especially when BAD is concomitant, but does not result
in significant changes in histopathology.17,100
5.5. A number of mucosal factors and mediators of
intestinal inflammation have been described in MC,
but none has reached clinical relevance
The cause of MC is unknown, but most likely involves a
specific mucosal immune response to luminal factors in
predisposed individuals. Numerous observational studies
have looked at different mechanisms that may be involved
in the development of the mucosal inflammation in MC, but
the pathophysiological importance of these findings are
uncertain (Table 3).
5.6. Drug-induced MC should be considered
Drug consumption has been suggested to act as an environ-
mental risk factor implicated as causative or triggering agent
of MC. Multiple drugs have been mentioned. For some of them
causality is considered to be certain, for other only probable or
possibly (Table 4). Criteria to define certainty (high likelihoodTable 4 Assessment of the level of likelihood that a specific dru
aModified from Beaugerie and Pardi.
High likelihood Interm
Acarbose123 Carbam
Aspirin and NSAIDs118,133–136 Celeco
Clozapine139 Duloxe
Entocapone142 Fluvas
Flavonoid124,137,143–147 b Flutam
Lansoprazole125,148–151 Oxetor
Omeprazole/Esomeprazole126 Madop
Ranitidine122 Paroxe
Sertraline11,127,137 Simvas
Ticlopidine29,138,156–159 Stalevo
a This paper used the ‘French algorithm’ to evaluate causality assessm
criteria belonging to two groups: chronological and semiological. Chrono
Semiological criteria are: Search for non-drug related causes, evocative se
and specific validated laboratory test. A bibliographic score taking into acc
calculate the total likelihood score of causality.
b Venotonic drugs containing flavonoids (diosmin, rutin, or hesperidi
c Anti-parkinsonian drugs, containing levodopa and benserazide (Madof causality) are based on a compatible timing of the start of
diarrhoea relative to drug exposure, improvement of the
symptoms after stopping the medication (dechallenge), and
recurrence of the symptoms on repeat exposure (rechallenge).
Case–control studies have shown the association of drug
usage with MC,115–118mainly for aspirin, NSAIDS, lansoprazole,
omeprazole, and sertraline consumption. However, in these
cases, a cause–effect relationship cannot be established. The
only report based on data from prescription databases found
no association with drug consumption.119
Drugs and their metabolites may affect the colon directly
through their pharmacological actions or through idiosyncratic
hypersensitivity reactions by the colonic mucosa. Drugs can
also act indirectly on the colon by altering colonisation by
gastrointestinal organisms. The rarity of an association between
a drug and MC favours the existence of an idiosyncratic
hypersensitivity reaction, i.e., it does not occur inmost patients
at any readily achieved dose of the drug and does not involve
the known pharmacologic effects of the drug.
Most of the drugs suggested to be associated with MC are
also well known to be associated with the development of
chronic diarrhoea as an adverse event.120 For example, in a
study on diarrhoea and drug use in the elderly, the use of
proton pump inhibitors, NSAIDs, and selective serotonin
reuptake inhibitors were associated with the risk of developing
diarrhoea.121 In a study on MC, use of some drugs presump-
tively associated with MC did not show significant differences
as compared to a chronic diarrhoea group.116 Therefore,
considering an association of a drug with MC should imply the
improving or disappearing of the histological damage after
dechallenge, and recurrence after rechallenge, and not only
the effect on the diarrhoea symptom. However, rechallenge
followed by clinical and histological relapse has been scarcely
reported.122–126
Further studies on the impact of medication discontinuation
on clinical symptoms and colonic histologywill help advance the
understanding of which is the true link between the drugs and
the disease.g can trigger MC: Review of the literature.127.
ediate likelihood Low likelihood
azepine11,128–131 Cimetidine132
xib137 Gold salts138
tine140 Piascledine141
tatin137
ide29,138
one152,153
ar154 c
tine11
tatin155
160 c
ent of adverse drug reactions. This implies the evaluation of seven
logical criteria are: Time to onset, dechallenge, and rechallenge.
miology of drug responsibility and/or risk factors for drug reaction,
ount how often the adverse reaction has been reportedwas used to
n).
oparR) and carbidopa, levodopa and entocapone (StalevoR).
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6.1. The choice of treatment in MC depends on
severity of symptoms
Medical treatment of MC should take into account the severity
of symptoms, their impact on the patient's quality of life, and
the availability of outcome data from randomized clinical
trials. The primary aim ofmedical therapy is to achieve clinical
remission and improve the patient's quality of life.59 In
patients with recurrent disease, the maintenance of clinical
remission may be desirable. It is currently not known whether
histological remission is relevant for the rate of recurrence,
and hence it is not clear whether it should be an important
goal.
6.2. Budesonide is the only drugwhich has
been proven effective in MC by randomized,
placebo-controlled trials
The strongest evidence from clinical trials for the treatment of
MC is currently available for budesonide.161 Three random-
ized, placebo-controlled trials in collagenous colitis have
proven budesonide at 9 mg per day to be effective for
induction of clinical remission.54–56 The majority of patients
respond rapidly to budesonide, and experience a substantial
improvement in quality of life.58,162 A Cochranemeta-analysis
revealed a pooled response rate of 81%, and a number-
needed-to-treat of two patients.163 After cessation of bude-
sonide treatment, symptomatic relapse may occur in 60–80%
of patients, most of whom respond to retreatment with
budesonide.37,55 Subsequently, two randomized placebo-
controlled trials have shown that clinical remission and
histological response can be maintained in the majority of
patients with budesonide at 6 mg per day for 6 months,38,164
with a pooled response rate of 83% and a number-needed-to-
treat of 2 patients.163
A similarly high efficacy of budesonide at 9 mg per day in LC
has been demonstrated by two randomized placebo-controlled
trials.165,166 A Cochrane meta-analysis revealed an odds ratio
of 9 for clinical response and a number-needed-to-treat of
3 patients.167 Both studies also demonstrated substantial
improvement of colonic inflammation.
6.3. There are currently no evidence-based
alternatives to budesonide
Antidiarrhoeals such as loperamide are frequently used in MC,
but have never been formally tested in randomized placebo-
controlled trials. Clinical experience suggests a symptomatic
benefit in some patients.11,12,159 However, sustained clinical
remission is rarely achieved, and an impact on colonic
inflammation is unlikely.
Prednisolone has been investigated in retrospective stud-
ies11,12,159 and in one small randomized, placebo-controlled
trial.57 A clinical response was noted in 5 of 8 patients after
2 weeks of prednisolone compared to none of 3 patients with
placebo.
Bismuth subsalicylate was tested in a small random-
ized placebo-controlled trial which has never been fullypublished.168 Clinical and histological responses were noted
in all 7 patients receiving bismuth subsalicylate and none of
the 7 receiving placebo.
Mesalazine for the treatment of MC has mainly been
reported in retrospective studies suggesting a therapeutic
response in about half of patients.11,12 At the time of writing,
there has only been one prospective but uncontrolled trial on
mesalazine,which showed a higher efficacywhen administered
over a period of 6 months.169 Due to lack of control groups, the
true value of mesalazine in MC remains inconclusive.
Retrospective studies suggest a benefit of cholestyramine
in MC.138,170,171 In a randomized study, 23 patients with CC
and 41 with LC received mesalazine at 2.4 g per day alone or
in combination with cholestyramine at 4 g per day for
6 months.171 Remission was noted in 91% of patients with
CC and 85% of patients with LC after 6 months; the combined
treatment appeared to be slightly better.
The probiotics Lactobacillus acidophilus LA-5 and Bifido-
bacterium animalis subspp. lactis BB12 (AB-Cap-10) given for
12 weeks did not show any benefit over placebo with respect
to clinical response, histological improvement, or quality of
life in a randomized placebo-controlled study in 29 patients
with CC.172 Boswellia serrata extract given at a dose of
3×400 mg per day for 6 weeks failed to show a significant
benefit over placebo in a randomized, placebo-controlled
trial. Clinical response was noted in 7 of 16 patients given
B. serrata extract (44%) compared to 4 of 15 given placebo
(27%). Neither histology nor quality of life was improved by
active treatment.173 The probiotic E. coli strain Nissle 1917
was investigated in an open-label uncontrolled trial in 14
patients with CC, administered at different dosages for at
least 4 weeks.174 A reduction in stool frequency was observed
in 64% of patients and an improvement of stool consistency in
50%.
Although the evidence is limited, immunosuppressive
therapies might be considered in patients with severe
symptoms who fail to respond to budesonide. In such cases,
azathioprine or 6-mercaptopurine have been tried in dosages
similar to those used for other inflammatory bowel disease.40
The first reports suggest that anti-TNF therapy may be
effective in refractory MC.175,176
Oral methotrexate has produced clinical response in
budesonide-naïve CC patients,177 but a recent report showed
no efficacy of methotrexate (25 mg s.c.) in patients that were
intolerant or refractory to budesonide.178 However, these data
remain limited and inconclusive, and treatment with immu-
nosuppressants or biologicals must therefore be regarded as
experimental.
Surgical intervention in microscopic colitis should be
regarded as ultima ratio in patients refractory to any
medical intervention. Both diverting ileostomy and subtotal
colectomy have been performed successfully in individual
cases.39,179
7. Summary: recommendations for the
treatment of MC
Based on the currently available evidence, the EMCGmembers
wish to propose a novel algorithm for the treatment of
microscopic colitis (Fig. 4). According to this algorithm,
patients with active MC should be primarily treated with
Figure 4 Treatment algorithm for active microscopic colitis.
940 A. Münch et al.short-term budesonide. Antidiarrhoeals and/or colestyramine
may be considered in patients with only mild symptoms,
however this recommendation is not evidenced-based. In case
of relapse after budesonide withdrawal, budsonide can be
used again either as intermittent or as low-dose continuous
therapy. In patients who do not respond to budesonide,
alternative drugs such as cholestyramine, aminosalicylates or
bismuth can be considered if symptoms are only mild.
There is currently no evidence to recommend azathioprine/
6-mercaptopurine or anti-TNF-α antibodies. However, there
are case reports to suggest that AZT/6-MP or TNF-α blockers
might be considered in individual cases. Surgical treatment
should be regarded as the last resort in patients refractory to
medical therapies.8. Future aspects
It is important to create awareness of MC among general
practitioners, gastroenterologists, surgeons, and patholo-
gists, as MC is a fairly “new” and frequent disease and should
always be considered in patients with chronic diarrhoea.
Numerous patients are still overlooked or even misdiagnosed
with IBS, and not referred to colonoscopy. Regular follow-
ups with a gastroenterologist should be conducted in order
to assess the disease course and discuss individual treatment
options if necessary.
Future research should focus on a better understanding
of the underlying pathophysiological and immunological
aberrations, as well as the finding of biomarkers that reflect
disease activity. The search for susceptibility genes in this
condition could give us deeper insight into pathogenic
processes such as the defectivemucosal barrier. Furthermore,
well designed studies should address the possibility of drug
aetiology in this condition.
One major unresolved question is whether MC is one
disease with different expressions, or several diseases. Thediagnosis of MC rests on strict but arbitrary histopathological
findings in colonic biopsies. Recent results indicate that the
histological findings in the individual patient are inconsis-
tent over time, as findings of MC interchange with chronic
inflammation or incomplete signs of MC at prior or repeated
endoscopy. The histological interchange between MC sub-
types and the incomplete identification of all patients have
led to the introduction of the term “incomplete MC” (MCi),
which needs further evaluation, including placebo-controlled
studies of the effect of budesonide treatment.
It is important to know which maintenance treatment is
most effective and safe in MC patients with a chronic, active
course. The 6 mg daily budesonide dose which has been used
is probably too high for long-term treatment in most elderly
people, and ongoing trials with lower doses are eagerly
awaited (EudraCT No: 2007-001315-31).
A further challenge is MC patients that fail to respond to
budesonide treatment. Although this subgroup of the MC
population is small, these patients have a very poor quality
of life and represent a real clinical challenge. Therefore,
randomized, controlled studies should investigate the efficacy
of immunosuppressive therapy, especially azathioprine/
6-mercaptopurine and anti-TNF therapy in patients that are
non-responders or intolerant to budesonide.Conflict of interest
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